ClinicalTrials.gg
CompletedNCT01201343SEPTIMEUpdated Dec 27, 2013Results posted

Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients

A Phase 4 interventional study of Interferon beta-1a in Multiple Sclerosis, Relapsing, Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
12th of 21
79 · median 80
Started
2005
with 3 others
Phase 4
13 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
5 of 21
Merck KGaA, Darmstadt, Germany

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 12th largest by enrollment, is one of 4 that started in 2005, is one of 13 in phase 4, and was the 15th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.

Read the detailed description

This study is planned to evaluate emotional disorders during treatment by IFN beta in RRMS subjects. This is an open-label, prospective, interventional, multicentric study with no change of therapeutic behavior but with standardized neuropsychologic follow-up. Subjects will undergo 13 evaluations (categorical and dimensional evaluations), 3 evaluations will be performed before the treatment (Baseline, Day 7 and 15) and 10 evaluations after the treatment (Month 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24).

03

Conditions studied

  • Multiple Sclerosis, Relapsing, Remitting

Keywords

  • Multiple sclerosis, relapsing, remitting
  • Interferon-beta
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged ≥ 18 years
  • Subjects with RRMS
  • Subjects with at least 2 relapses in the past two years (with last relapse finished or finishing)
  • Subjects with indication of IFN beta treatment determined by the investigator
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Subjects with secondary progressive multiple sclerosis (MS) without relapse
  • Subjects with ongoing acute relapse
  • Subjects already being treated with interferon
  • Subjects with corticoid therapy for less than 15 days
  • Subjects presenting acute major depression or treated with anti-depressant therapy
  • Subjects involved in another therapeutic study
  • Subjects with any condition which could interfere with a good compliance of this study
  • Other protocol-defined exclusion criteria may apply
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Emotional Dyscontrol Sub-score of the Depressive Mood Scale (Echelle d'Humeur Depressive [EHD]) Scale at Month 12

    EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

    Time frame: Baseline and Month 12

  2. Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18

    EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

    Time frame: Baseline and Month 18

  3. Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24

    EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

    Time frame: Baseline and Month 24

Secondary outcomes

  1. Change From Baseline in Emotional Abrasion Sub-score of the EHD Scale at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

    EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional abrasion sub-score is the sum of items 3, 6, 7, and 8. The total possible score range from 1 (not at all) to 16 (very much), where 16 corresponds to worst state. (Radat F et al., 2007)

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

  2. Change From Baseline in State-trait Anxiety Inventory (STAI State) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

    STAI state scale is an auto-evaluation scale for anxiety. This scale includes 20 items that allow quantifying feeling of apprehension, tension, nervousness and worry that the participant feels at the time of the completion of the questionnaire. The 20 items are graded from 1 (no) to 4 (yes), where 'yes' corresponds to the best state for items 1, 2, 5, 8, 10, 11, 15, 16, 19, 20 (scoring was reversed before calculation of total score); and to the worst state for items 3, 4, 6, 7, 9, 12, 13, 14, 17, 18. The total score ranged from 1 (best state) to 80 (worst state). (Spielberger CD et al., 1983)

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

  3. Change From Baseline in Center for Epidemiologic Studies Depression (CES-D) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

    CES-D is an auto-questionnaire including 20 items to screen for depressive feelings and behaviour. The 20 items of this scale are graded from 0 (never) to 3 (always), where 3 corresponds to the most severe state with the exception of items 4, 8, 12 and 16 (scoring was reversed before the calculation of the total score). Total score ranged from 0 (never) to 60 (always), where 60 corresponds to most severe state. (Radloff LS, 1977)

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

  4. Change From Baseline in Center for State-trait Anger Expression Inventory 2 (STAXI-state) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

    STAXI-state scale measures the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). In this study only 1 of the original 6 scales was used, the state anger scale, which measures the intensity of anger at a given moment as emotional state. This scale consists of 15 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The total score range from 1 (not at all) to 60 (very much), where 60 corresponds to the worst state. (Spielberger CD, 1996)

    Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

  5. Change From Baseline in Fatigue Score at Months 1, 2, 3, 6, 12 and 24

    Fatigue scale was derived from the United Kingdom Neurological Disability Scale (UKNDS), and evaluates fatigue according to the participant's subjective impression and the functional disability that it causes. 'Yes' or 'No' answers result in a score that ranges from 0 to 5, where a score 5 shows worse state. (Sharrack B et al., 1999)

    Time frame: Baseline, Months 1, 2, 3, 6, 12, and 24

07

Results

Posted Apr 11, 2012

Participant flow

Participant flow — Overall Study
MilestoneInterferon-beta
Started79
Treated76
Completed60
Not completed19
Withdrew: Adverse event6
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up2
Withdrew: Lack of efficacy2
Withdrew: Participant wrongly included in trial1
Withdrew: Randomized, not treated3

Outcome measures

PrimaryChange From Baseline in Emotional Dyscontrol Sub-score of the Depressive Mood Scale (Echelle d'Humeur Depressive [EHD]) Scale at Month 12

EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

Time frame:
Baseline and Month 12
Reported as:
Mean · units on a scale
Change From Baseline in Emotional Dyscontrol Sub-score of the Depressive Mood Scale (Echelle d'Humeur Depressive [EHD]) Scale at Month 12
units on a scaleInterferon-beta
Baseline (n= 70)12.7 ± 4.4
Change at Month 12 (n= 57)-0.5 ± 4.2
PrimaryChange From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18

EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

Time frame:
Baseline and Month 18
Reported as:
Mean · units on a scale
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18
units on a scaleInterferon-beta
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18-0.6 ± 4.6
PrimaryChange From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24

EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)

Time frame:
Baseline and Month 24
Reported as:
Mean · units on a scale
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24
units on a scaleInterferon-beta
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24-0.1 ± 5.2
SecondaryChange From Baseline in Emotional Abrasion Sub-score of the EHD Scale at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional abrasion sub-score is the sum of items 3, 6, 7, and 8. The total possible score range from 1 (not at all) to 16 (very much), where 16 corresponds to worst state. (Radat F et al., 2007)

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Emotional Abrasion Sub-score of the EHD Scale at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
units on a scaleInterferon-beta
Baseline (n= 70)5.6 ± 1.6
Change at Month 1 (n= 64)0.3 ± 1.6
Change at Month 2 (n= 62)-0.1 ± 1.7
Change at Month 3 (n= 64)-0.0 ± 1.6
Change at Month 4 (n= 59)-0.0 ± 1.8
Change at Month 5 (n= 58)-0.2 ± 1.5
Change at Month 6 (n= 56)-0.3 ± 1.8
Change at Month 9 (n= 58)-0.1 ± 1.8
Change at Month 12 (n= 57)-0.0 ± 2.3
Change at Month 18 (n= 61)-0.3 ± 1.9
Change at Month 24 (n= 63)-0.3 ± 1.7
SecondaryChange From Baseline in State-trait Anxiety Inventory (STAI State) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

STAI state scale is an auto-evaluation scale for anxiety. This scale includes 20 items that allow quantifying feeling of apprehension, tension, nervousness and worry that the participant feels at the time of the completion of the questionnaire. The 20 items are graded from 1 (no) to 4 (yes), where 'yes' corresponds to the best state for items 1, 2, 5, 8, 10, 11, 15, 16, 19, 20 (scoring was reversed before calculation of total score); and to the worst state for items 3, 4, 6, 7, 9, 12, 13, 14, 17, 18. The total score ranged from 1 (best state) to 80 (worst state). (Spielberger CD et al., 1983)

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Reported as:
Mean · units on a scale
Change From Baseline in State-trait Anxiety Inventory (STAI State) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
units on a scaleInterferon-beta
Baseline (n= 70)35.9 ± 11.8
Change at Month 1 (n= 65)0.8 ± 10.5
Change at Month 2 (n= 62)0.3 ± 12.3
Change at Month 3 (n= 64)-1.7 ± 11.5
Change at Month 4 (n= 59)-1.5 ± 11.0
Change at Month 5 (n= 58)-0.8 ± 9.2
Change at Month 6 (n= 55)-1.4 ± 11.5
Change at Month 9 (n= 58)-0.2 ± 10.5
Change at Month 12 (n= 57)-0.3 ± 12.7
Change at Month 18 (n= 61)-1.2 ± 11.2
Change at Month 24 (n= 63)-1.4 ± 13.1
SecondaryChange From Baseline in Center for Epidemiologic Studies Depression (CES-D) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

CES-D is an auto-questionnaire including 20 items to screen for depressive feelings and behaviour. The 20 items of this scale are graded from 0 (never) to 3 (always), where 3 corresponds to the most severe state with the exception of items 4, 8, 12 and 16 (scoring was reversed before the calculation of the total score). Total score ranged from 0 (never) to 60 (always), where 60 corresponds to most severe state. (Radloff LS, 1977)

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Center for Epidemiologic Studies Depression (CES-D) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
units on a scaleInterferon-beta
Baseline (n= 70)13.5 ± 11.1
Change at Month 1 (n= 65)1.0 ± 8.6
Change at Month 2 (n= 62)1.5 ± 10.6
Change at Month 3 (n= 64)-0.5 ± 9.9
Change at Month 4 (n= 58)-1.0 ± 9.8
Change at Month 5 (n= 58)-1.1 ± 8.6
Change at Month 6 (n= 56)0.9 ± 9.2
Change at Month 9 (n= 58)0.9 ± 10.7
Change at Month 12 (n= 57)1.6 ± 10.8
Change at Month 18 (n= 61)-0.2 ± 9.0
Change at Month 24 (n= 63)0.1 ± 10.1
SecondaryChange From Baseline in Center for State-trait Anger Expression Inventory 2 (STAXI-state) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24

STAXI-state scale measures the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). In this study only 1 of the original 6 scales was used, the state anger scale, which measures the intensity of anger at a given moment as emotional state. This scale consists of 15 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The total score range from 1 (not at all) to 60 (very much), where 60 corresponds to the worst state. (Spielberger CD, 1996)

Time frame:
Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Reported as:
Mean · units on a scale
Change From Baseline in Center for State-trait Anger Expression Inventory 2 (STAXI-state) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
units on a scaleInterferon-beta
Baseline (n= 70)16.8 ± 4.1
Change at Month 1 (n= 65)0.0 ± 4.2
Change at Month 2 (n= 62)1.0 ± 5.3
Change at Month 3 (n= 64)-0.0 ± 5.3
Change at Month 4 (n= 59)-0.3 ± 4.7
Change at Month 5 (n= 58)-0.0 ± 2.9
Change at Month 6 (n= 56)1.1 ± 7.6
Change at Month 9 (n= 58)1.1 ± 5.9
Change at Month 12 (n= 57)0.9 ± 5.7
Change at Month 18 (n= 61)0.8 ± 5.4
Change at Month 24 (n= 63)1.0 ± 5.5
SecondaryChange From Baseline in Fatigue Score at Months 1, 2, 3, 6, 12 and 24

Fatigue scale was derived from the United Kingdom Neurological Disability Scale (UKNDS), and evaluates fatigue according to the participant's subjective impression and the functional disability that it causes. 'Yes' or 'No' answers result in a score that ranges from 0 to 5, where a score 5 shows worse state. (Sharrack B et al., 1999)

Time frame:
Baseline, Months 1, 2, 3, 6, 12, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Fatigue Score at Months 1, 2, 3, 6, 12 and 24
units on a scaleInterferon-beta
Baseline (n= 62)2.1 ± 1.7
Change at Month 1 (n= 58)0.5 ± 1.6
Change at Month 2 (n= 55)0.4 ± 1.5
Change at Month 3 (n= 56)0.2 ± 1.8
Change at Month 6 (n= 50)0.4 ± 1.8
Change at Month 12 (n= 49)0.1 ± 1.8
Change at Month 24 (n= 56)-0.1 ± 2.1

Adverse events

Collected over Baseline to Month 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interferon-beta—9/76 (11.8%)62/76 (81.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventInterferon-beta
DepressionPsychiatric disorders3/76
Lung DisorderRespiratory, thoracic and mediastinal disorders1/76
Sudden Hearing LossEar and labyrinth disorders1/76
AbortionPregnancy, puerperium and perinatal conditions1/76
AnxietyPsychiatric disorders1/76
HeadacheNervous system disorders1/76
Drug DependencePsychiatric disorders1/76
AggressivityPsychiatric disorders1/76
Suicide AttemptPsychiatric disorders1/76
Neck InjuryInjury, poisoning and procedural complications1/76
Most frequent other events
Showing 10 of 71
Most frequent other events
EventInterferon-beta
Multiple Sclerosis RelapseNervous system disorders40/76
Influenza Like IllnessGeneral disorders18/76
FatigueGeneral disorders11/76
Injection Site PainGeneral disorders7/76
DepressionPsychiatric disorders6/76
Injection Site ErythemaGeneral disorders5/76
Pain in ExtremityMusculoskeletal and connective tissue disorders4/76
Cytolytic HepatitisHepatobiliary disorders3/76
HeadacheNervous system disorders2/76
MigraineNervous system disorders2/76

Baseline characteristics

Age, Continuous
Age, Continuous(years)Interferon-beta
Mean37.0 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Interferon-beta
Female56
Male14
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Radat F, Lafittau M, Ouallet JC, Brochet B, Jouvent R. [Validation of EHD self questionnaire in multiple sclerosis]. Encephale. 2007 Jan-Feb;33(1):49-57. doi: 10.1016/s0013-7006(07)91558-4. French. PubMed 17457294 ↗
  • Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999 Aug;5(4):223-33. doi: 10.1177/135245859900500406. PubMed 10467380 ↗
  • Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press
  • Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977;1:385-401.
  • Spielberger CD. Manual for the State-Anger Expression Inventory. Odessa, FL: Psychological Assessment Resources; 1996
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2010
First posted
Sep 14, 2010
Start
Jan 2005
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Apr 11, 2012
Last update
Dec 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01201343
Collaborators
Merck Serono S.A.S, France
Responsible party
Sponsor
First posted
Sep 14, 2010
Start date
Jan 2005
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Apr 11, 2012
Last update
Dec 27, 2013

Study contacts

Bruno Brochet, MD, Prof.
principal investigator · Hôpital PELLEGRIN, Place Amélie Raba Léon 33076 BORDEAUX Cedex

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion